| Literature DB >> 34249933 |
Di Lu1, Yan Xu1, Qiuli Liu1, Qi Zhang1.
Abstract
Macrophages are involved in almost every aspect of biological systems and include development, homeostasis and repair. Mesenchymal stem cells (MSCs) have good clinical application prospects due to their ability to regulate adaptive and innate immune cells, particularly macrophages, and they have been used successfully for many immune disorders, including inflammatory bowel disease (IBD), acute lung injury, and wound healing, which have been reported as macrophage-mediated disorders. In the present review, we focus on the interaction between MSCs and macrophages and summarize their methods of interaction and communication, such as cell-to-cell contact, soluble factor secretion, and organelle transfer. In addition, we discuss the roles of MSC-macrophage crosstalk in the development of disease and maintenance of homeostasis of inflammatory microenvironments. Finally, we provide optimal strategies for applications in immune-related disease treatments.Entities:
Keywords: clinic therapy; homeostasis; macrophage; mesenchymal stem cells; microenvironment
Year: 2021 PMID: 34249933 PMCID: PMC8267370 DOI: 10.3389/fcell.2021.681171
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
FIGURE 1The characteristics of macrophages.
FIGURE 2The crosstalk between MSCs and macrophages.
MSC-macrophage crosstalk in different diseases/in vitro system.
| Liver | Liver fibrosis | MSC-sEVs induce CX3CR1 + anti-inflammation macrophage | Ameliorated inflammation and fibrosis | |
| Ischemia/Reperfusion (IR)-induced sterile inflammatory liver injury | MSC reprogram macrophage toward anti-inflammatory M2 phenotype | Reduced hepatocellular damage; Diminished liver inflammation | ||
| Acute liver failure | MSC induced anti-inflammatory (M2) macrophages; reduced levels of macrophage | Ameliorated hepatocyte death and liver inflammatory response. | ||
| Liver regeneration | Decreased CD68+ macrophages. | Stimulated liver regeneration in rat. | ||
| Heart | Acute rejection of heart transplantation | Inhibited M1 and promoted M2 polarization | Inhibit STAT1 and NF-kB pathways; Inhibit the acute rejection of heart transplantation in mice. | |
| Diabetic cardiomyopathy (DCM) | COX-2-PGE2 pathway to promote M2 macrophage polarization | Ameliorate myocardial injury caused by diabetic cardiomyopathy. | ||
| Myocardial infarction | Secreting periostin to promote the polarization of M2 macrophage. Reduced pan-macrophage infiltration | Improved cardiac function, decreased infarct size. | ||
| Atherosclerosis | Stimulate the production of anti-inflammatory factor IL-10, and reduce the production of TNF-α by macrophage. | Reduce atherosclerotic plaque. | ||
| Intestine | Colitis | Chemokine interactome dictates the induction of IL-10+ macrophages and promote M2 polarization. | Mitigate gut injury | |
| Inflammatory bowel disease | Up-regulate the expression of IL-10 and promote M2 polarization. | Alleviate inflammatory bowel disease | ||
| Lung | Acute lung injury | Promote M2 macrophage polarization. | Ameliorate acute lung injury induced by LPS. | |
| Pulmonary arterial | Attenuate the CD68+ macrophage and induce the CD163+ macrophage | Reduce lung inflammation and vascular remodeling Improve hemodynamics in experimental pulmonary arterial hypertension; Ameliorate the impaired alveolarization and pulmonary artery remodeling | ||
| Acute Respiratory Distress Syndrome | Mitochondrial transfer via tunneling nanotubes to enhance macrophage phagocytosis. | Improve bacteria clearance rate, reduce disease response, and have obvious antibacterial effect | ||
| Wound healing | Diabetic wound healing | MSC polarizes macrophages to M2 type through MSC-Exos and PGE2- dependent pathways | Relieve inflammation and autoimmune response | |
| Cutaneous wound healing | Inhibit NF-kB pathway to promote the polarization of M2 macrophages | Promote cutaneous wound healing, reduce scar areas and the infiltration of inflammatory cells | ||
| Cancer | Suppress leukemia | Reprogram macrophages to the arginine-1 positive phenotype. | Change the bone marrow microenvironment and inhibit the development of leukemia. | |
| Breast cancer | Secrete exosomes to promote myeloid cells into M2-polarized breast cancer macrophages | Drive accelerated breast cancer progression | ||
| Lung cancer | Increased miR-21-5p delivery by MSC-EV after hypoxia pre-challenge by reducing apoptosis and promoting macrophage M2 polarization. | Promote lung cancer development | ||
| Bone | Bone tissue repair | Secrete TGF-β to promote the transition from M1 to M2 macrophages; the transition of M1 to M2 is beneficial of proliferation and osteogenic differentiation of MSCs | Initiate bone regeneration and promote bone tissue repair | |
| Mouse-derived bone marrow MSCs are cocultured with macrophages | MSC stimulates macrophage secretion of IL-10 through PGE2; TNF-α and iNOS expressed by macrophages are necessary for MSCs to secrete PGE2. | Reduced mortality and improved organ function and cultured banked human BMSCs may be effective in treating sepsis. | ||
| MAPC cocultured with monocytes | Macrophage cytokines can produce inflammatory cytokines to stimulate MSC to produce PGE2 and blood cytokines IL-1RA | Suppress the IL-7-dependent T-cell expansion | ||
| Coculture of MSC and macrophage in Murine inflammatory environment | Inducing macrophages to produce IL-10 is also partly involved in the beneficial effects of MSC-Exos | Reduce murine colonic inflammation | ||
| MSC coculture with pro-inflammatory macrophage | Promotes the interaction of CD200 and CD200R on MSCs and the anti-inflammatory transformation of macrophages increases the production of TSG-6 by MSC | Enhance the inhibitory regulation of MSCs on T cells and macrophages |